Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12033243 | 0.86 | BUB1 (0.35) | BUB1HSP90AA1HSP90AB1BCHEGPR119 | |
| SCHEMBL16475122 | 0.79 | RET (0.40) | BUB1GPR119SLC22A12 | |
| SCHEMBL21565885 | 0.76 | ACLY (0.38) | BUB1HSP90AA1HSP90AB1BCHEGPR119 | |
| SCHEMBL30500251 | 0.76 | ACLY (0.38) | BUB1HSP90AA1HSP90AB1BCHEGPR119 | |
| SCHEMBL31549560 | 0.74 | BUB1 (0.39) | BUB1HSP90AA1HSP90AB1BCHEGPR119 | |
| SCHEMBL29128021 | 0.73 | BUB1 (0.39) | BUB1HSP90AA1HSP90AB1BCHEGPR119 | |
| SCHEMBL25648570 | 0.72 | ALDH1A1 (0.36) | BUB1HSP90AA1HSP90AB1BCHEL3MBTL1 | |
| SCHEMBL12832975 | 0.72 | BUB1 (0.38) | BUB1HSP90AA1HSP90AB1BCHEGPR119 | |
| SCHEMBL31370728 | 0.71 | CSNK2A1 (0.37) | BCHEGPR119HTR6POLBL3MBTL1 | |
| SCHEMBL31751884 | 0.71 | BCHE (0.35) | BUB1BCHEGPR119GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132188-B2 | Chemically Programmed Vaccination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-15 | — | — | US | disclosed |
| US-9132188-B2 | Chemically Programmed Vaccination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-15 | — | — | US | disclosed |
| US-8518927-B2 | Chemically programmed vaccination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518927-B2 | Chemically programmed vaccination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110311516-A1 | Chemically Programmed Vaccination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311516-A1 | Chemically Programmed Vaccination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311516-A1 | Chemically Programmed Vaccination | CD69, CD4, ICOS | BUB1 2111/4885HSP90AA1 692/4885HSP90AB1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.